JELMYTO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Jelmyto, and what generic alternatives are available?
Jelmyto is a drug marketed by Urogen Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has nine patent family members in six countries.
The generic ingredient in JELMYTO is mitomycin. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mitomycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jelmyto
A generic version of JELMYTO was approved as mitomycin by HIKMA on April 19th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JELMYTO?
- What are the global sales for JELMYTO?
- What is Average Wholesale Price for JELMYTO?
Summary for JELMYTO
International Patents: | 9 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 6 |
Patent Applications: | 4,558 |
Drug Prices: | Drug price information for JELMYTO |
What excipients (inactive ingredients) are in JELMYTO? | JELMYTO excipients list |
DailyMed Link: | JELMYTO at DailyMed |
Recent Clinical Trials for JELMYTO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
City of Hope Medical Center | Phase 2 |
Mayo Clinic | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for JELMYTO
JELMYTO is protected by two US patents and one FDA Regulatory Exclusivity.
Patents protecting JELMYTO
Material and method for treating internal cavities
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Material and method for treating internal cavities
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting JELMYTO
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for JELMYTO
See the table below for patents covering JELMYTO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 230530 | חומרים ושיטה לטיפול בחללים של הגוף (Materials and method for treating internal body cavities) | ⤷ Sign Up |
Israel | 221040 | חומר ושיטה לטיפול בחללי גוף פנימיים (Material and method for treating internal cavities) | ⤷ Sign Up |
Denmark | 2525777 | ⤷ Sign Up | |
Spain | 2732150 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |